Healthcare Sales & Marketing Network News: efavirenz

Searching News Database: efavirenz

HSMN NewsFeed - 28 Mar 2018
Mylan Introduces Symfi(TM) Triple Combo Once-Daily HIV Treatment in the U.S.
Biopharmaceuticals HIV/AIDS FDA Product Launch

HSMN NewsFeed - 2 Mar 2018
Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
Biopharmaceuticals HIV/AIDS Product Launch

HSMN NewsFeed - 1 Feb 2018
Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva(R) Tablets
Biopharmaceuticals HIV/AIDS Generics Product Launch

HSMN NewsFeed - 10 Aug 2017
Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 19 May 2017
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS(R) (raltegravir) 600 mg in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Jul 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 28 Sep 2015
AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Jan 2014
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 3 May 2013
Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA(R) (efavirenz) in HIV-1 Infected Pediatric Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 20 Sep 2011
Mylan's Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 3 Sep 2010
Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 22 Dec 2009
Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 20 Nov 2009
FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Oct 2009
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry for Use in Patients Starting HIV Therapy for the First Time
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 16 Sep 2009
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 15 Sep 2009
European Union Commission Approves Expanded Use of ISENTRESS(R) (raltegravir), from MSD, in Adult Patients with HIV-1 Infection
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 18 Aug 2009
Mylan's Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Aug 2008
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 1 Aug 2008
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
Biopharmaceuticals HIV/AIDS Distribution

HSMN NewsFeed - 6 Feb 2008
Pfizer Presents New Data from HIV/AIDS Portfolio at Conference on Retroviruses and Opportunistic Infections
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 21 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals FDA HIV/AIDS

HSMN NewsFeed - 19 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 11 Dec 2007
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 4 Dec 2007
Myriad Genetics Submits IND on Vivecon
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 12 Nov 2007
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 29 Oct 2007
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 18 Oct 2007
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 17 Oct 2007
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 25 Jul 2007
Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 23 Jul 2007
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 17 May 2007
Health Canada approves REYATAZ(R) (atazanavir sulfate) 300 mg single capsule formulation in combination therapy for adults with HIV-1 infection
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 4 May 2007
Merck & Co., Inc. Statement on Brazilian Government's Decision To Issue Compulsory License for STOCRIN(TM)
Biopharmaceuticals Generics HIV/AIDS

HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 16 Feb 2007
Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing Countries
Biopharmacetuicals HIV/AIDS

HSMN NewsFeed - 22 Dec 2006
Company Announces Acquisition of Research and Development Programs, Hiring of Senior Management Team and Name Change
Biopharmaceuticals Acquisitions Personnel

HSMN NewsFeed - 15 Dec 2006
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 20 Oct 2006
FDA Approves REYATAZ(R) (atazanavir sulfate) 300 mg Single Capsule Formulation in Combination Therapy for Adults With HIV-1 Infection
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 9 Oct 2006
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 29 Sep 2006
Bristol-Myers Squibb and Gilead Sciences establish agreement to commercialize ATRIPLA(TM) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Canada
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Sep 2006
Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 12 Jul 2006
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Biopharmaceuticals FDA HIV/AIDS

Return to NewsFeed

Additional items found! 36

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 36 additional stories matching:
efavirenz
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.